Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Updated . What changed?
GRAYBUG VISION, INC. is a biotechnology business based in the US. GRAYBUG VISION shares (GRAY) are listed on the NASDAQ and all prices are listed in US Dollars. GRAYBUG VISION employs 24 staff and has a market cap (total outstanding shares value) of USD$310.4 million.
|Latest market close||USD$15.9|
|52-week range||USD$12.5 - USD$20.74|
|50-day moving average||USD$14.575|
|200-day moving average||USD$14.575|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-14)||-1.67%|
|1 month (2020-09-18)||N/A|
|3 months (2020-07-18)||N/A|
|6 months (2020-04-18)||N/A|
|1 year (2019-10-18)||N/A|
|2 years (2018-10-18)||N/A|
|3 years (2017-10-18)||N/A|
|5 years (2015-10-18)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$310.4 million|
TTM: trailing 12 months
There are currently 174,598 GRAYBUG VISION shares held short by investors – that's known as GRAYBUG VISION's "short interest". This figure is up from 0 last month.
There are a few different ways that this level of interest in shorting GRAYBUG VISION shares can be evaluated.
GRAYBUG VISION's "short interest ratio" (SIR) is the quantity of GRAYBUG VISION shares currently shorted divided by the average quantity of GRAYBUG VISION shares traded daily (recently around 646659.25925926). GRAYBUG VISION's SIR currently stands at 0.27. In other words for every 100,000 GRAYBUG VISION shares traded daily on the market, roughly 270 shares are currently held short.
To gain some more context, you can compare GRAYBUG VISION's short interest ratio against those of similar companies.
However GRAYBUG VISION's short interest can also be evaluated against the total number of GRAYBUG VISION shares, or, against the total number of tradable GRAYBUG VISION shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GRAYBUG VISION's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GRAYBUG VISION shares in existence, roughly 10 shares are currently held short) or 0.0174% of the tradable shares (for every 100,000 tradable GRAYBUG VISION shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GRAYBUG VISION.
Find out more about how you can short GRAYBUG VISION stock.
We're not expecting GRAYBUG VISION to pay a dividend over the next 12 months.
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Steps to owning and managing MHO, with 24-hour and historical pricing before you buy.
Steps to owning and managing HLIT, with 24-hour and historical pricing before you buy.
Steps to owning and managing XELA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PDD, with 24-hour and historical pricing before you buy.
Steps to owning and managing JAKK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IMMU, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRCP, with 24-hour and historical pricing before you buy.
Steps to owning and managing MNRO, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMRX, with 24-hour and historical pricing before you buy.
Steps to owning and managing YUM, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.